Too little, too late: chasing atrial fibrillation with sodium channel antagonists.
Anderson
Mark E
ME
D000200:Action Potentials; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D005424:Flecainide / Q000494:pharmacology / Q000627:therapeutic use; D006329:Heart Conduction System / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use; D026902:Potassium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D026941:Sodium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors
D000889:Anti-Arrhythmia Agents; D007093:Imidazoles; D026902:Potassium Channel Blockers; D026941:Sodium Channel Blockers; D005424:Flecainide; C032151:cifenline